Jiangsu Kunli Biopharmaceutical

Jiangsu Kunli Biopharmaceutical is a clinical-stage biotechnology company based in China, dedicated to the research, development, and industrialization of recombinant vaccines. The company operates out of the China Medical City in Taizhou, where it maintains a large-scale GMP-compliant manufacturing facility and an integrated R&D center. Kunli's core technology focuses on recombinant protein expression and novel adjuvant systems designed to enhance immune responses. Its most advanced program, KL-001, is a recombinant herpes zoster vaccine currently undergoing Phase 3 clinical evaluation. Beyond shingles, the company is advancing a diverse pipeline targeting high-burden pathogens including Human Papillomavirus (HPV), Respiratory Syncytial Virus (RSV), and Norovirus. Backed by prominent investors like HighLight Capital, Kunli aims to provide affordable, high-quality domestic vaccine alternatives for the global market.